Beyond Acid Suppression: Mechanistic and Translational Perspectives on the Pleiotropic Pharmacology of Pantoprazole

Pantoprazole is widely used for the management of acid-related gastrointestinal disorders through inhibition of the gastric H+/K+-ATPase. Beyond its established acid-suppressive action, experimental studies have investigated its potential effects on cellular proton homeostasis, autophagy, oxidative and inflammatory signaling, cancer biology, antimicrobial resistance, glucose regulation, neurological responses, hepatic fibrosis, and iron-related outcomes. This narrative review critically examines these proposed biological effects and distinguishes established pharmacology from experimental mechanisms, preclinical findings, and human clinical evidence. Particular attention is given to the relationship between experimental concentrations and human exposure, the acid-dependent activation of pantoprazole, the distinction between direct molecular targets and downstream cellular responses, and the challenges of translating laboratory findings into clinical benefit. Pantoprazole also has a comparatively favorable CYP2C19-mediated drug-interaction profile relative to omeprazole and esomeprazole, although this advantage does not imply the absence of all clinically relevant interactions. The evidence across proposed repurposing indications remains heterogeneous, and biological activity in experimental models should not be interpreted as established therapeutic efficacy. Further exposure-informed mechanistic studies, pharmacokinetic and pharmacodynamic validation, and appropriately designed clinical trials are required to determine which proposed effects warrant clinical development. Pantoprazole should therefore be regarded as a candidate for mechanism-informed drug-repurposing research rather than an established treatment for the non-gastrointestinal indications discussed in this review.